LLY - AbCellera-discovered bamlanivimab combo shows promise in late-stage COVID-19 trial

AbCellera ([[ABCL]] +6.0%) announces that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly (LLY), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19.The results from this new randomized, double-blind, placebo-controlled Phase 3 BLAZE-1 study provide additional efficacy and safety data that support the use of the dose recently granted both EUA by the U.S. FDA, and a positive scientific opinion by the EMA CHMP.87% reduction in COVID-19-related hospitalizations and deaths versus placebo (p<0.0001).No COVID-19-related deaths in the treatment group. All deaths occurred in patients treated with the placebo.Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union, the company said.

For further details see:

AbCellera-discovered bamlanivimab combo shows promise in late-stage COVID-19 trial